Saxena Kunal, Dempsey Amanda, Verma Rishi P, Martinez Rebecca, Schmier Jordana K, Zimet Gregory D
Outcomes Research, Merck & Co., Inc., Rahway, NJ, USA.
US Medical Affairs, Merck & Co., Inc., Rahway, NJ, USA.
Hum Vaccin Immunother. 2025 Dec;21(1):2561455. doi: 10.1080/21645515.2025.2561455. Epub 2025 Sep 22.
This study investigated health care providers' (HCPs') attitudes and experiences with initiating HPV vaccination at 9-10 y old instead of 11-12 y old. We conducted a cross-sectional online survey with 500 US HCPs who reported recommending and/or administering HPV vaccination to pediatric patients, recruited from a membership-based panel. The survey focused on providers' experiences with, and attitudes toward, routine HPV vaccination at age 9-10. Participants included pediatricians (n = 175), family medicine physicians (n = 175), nurse practitioners (n = 75), and physician assistants (n = 75). HCPs were mostly female (56%), white (79%), with a mean age of 43 y. HCPs reported the HPV vaccine to boys and girls before age 11 72% and 77% of the time, respectively, but it prior to age 11 less frequently (38% and 51% of the time). Few HCPs (11%) reported introducing the vaccine at the same visit at which it was given; 36% reported multiple discussions before acceptance. A substantial proportion of HCPs (23%) would not administer HPV vaccine when children were <11 y old, even if asked by parents. HCPs reported that a majority of parents who were offered HPV vaccination for their children at 9-10 y of age accepted. HCPs identified benefits of earlier vaccination; the top three were improving on-time completion, completion prior to other adolescent vaccines and increased opportunities to vaccinate. Top concerns included parent misconception about the duration of protection and difficulty explaining HPV vaccination to a younger child. Findings suggest most HCPs would support earlier HPV vaccination and see potential for improved completion.
本研究调查了医疗保健提供者(HCP)对于在9至10岁而非11至12岁开始接种人乳头瘤病毒(HPV)疫苗的态度和经历。我们对500名美国HCP进行了一项横断面在线调查,这些HCP报告曾向儿科患者推荐和/或接种HPV疫苗,他们是从一个基于会员的小组中招募的。该调查聚焦于提供者在9至10岁时进行常规HPV疫苗接种的经历和态度。参与者包括儿科医生(n = 175)、家庭医学医生(n = 175)、执业护士(n = 75)和医师助理(n = 75)。HCP大多为女性(56%),白人(79%),平均年龄43岁。HCP分别在11岁之前72%和77%的时间向男孩和女孩报告过HPV疫苗,但在11岁之前报告的频率较低(分别为38%和51%的时间)。很少有HCP(11%)报告在接种疫苗的同一次就诊时介绍疫苗;36%报告在接受接种前进行过多次讨论。相当一部分HCP(23%)即使在家长要求时,也不会给11岁以下儿童接种HPV疫苗。HCP报告称,大多数在孩子9至10岁时被提供HPV疫苗接种的家长接受了接种。HCP确定了早期接种疫苗的好处;排在前三位的是提高按时完成接种率、在接种其他青少年疫苗之前完成接种以及增加接种机会。最主要的担忧包括家长对保护期限的误解以及向年幼孩子解释HPV疫苗接种的困难。研究结果表明,大多数HCP会支持更早接种HPV疫苗,并认为有提高完成率的潜力。